Primary Job Title CEO Primary Organization SelectION
Location San Diego, California, United States Regions Greater San Diego Area, West Coast, Western US Gender Male
Investor Type
LinkedIn View on LinkedIn
Dr. Antonius Schuh has been the chief executive for a series of successful start-up molecular diagnostic companies. Currently he is the chief executive officer of Trovagene, a company specializing in the detection and analysis of transrenal nucleic acids in urine.
Prior to Trovagene, Dr. Schuh served as chairman and chief executive officer of
Sorrento Therapeutics, Inc., a biotechnology company he co-founded based on a proprietary platform to generate fully human mAb libraries. Previously, he was the founding CEO of AviaraDx, Inc., a leading molecular diagnostic innovator in oncology, where he led its sale to bioMérieux.
Before AviaraDx, he served as CEO of Arcturus Bioscience, Inc., where he led the sale of Arcturus’ life science business to Molecular Devices, Inc., now part of MDS. Prior to Arcturus, Dr. Schuh served as the president and chief executive officer of Sequenom, Inc.
He joined Sequenom as managing director of the company’s German operations, Sequenom GmbH, from Helm AG of Hamburg, an international trading and distribution corporation for chemical and pharmaceutical products. At Helm, he headed the business development group of the pharmaceutical division and the associated technical and regulatory affairs department.
Dr. Schuh is a certified pharmacist and earned his Ph.D. in medicinal chemistry from the University of Bonn, Germany. He currently also serves as a director Transgenomic, Inc. and Sorrento Therapeutics, Inc.
